This is a preview of subscription content, log in via an institution to check access.
References
Cigana C, Assael BM, Melotti P (2007) Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51:975–981. https://doi.org/10.1128/AAC.01142-06
Kawamura K, Ichikado K, Takaki M et al (2016) Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. SpringerPlus 5:1193. https://doi.org/10.1186/s40064-016-2866-1
Walkey AJ, Wiener RS (2012) Macrolide antibiotics and survival in patients with acute lung injury. Chest 141:1153–1159. https://doi.org/10.1378/chest.11-1908
Giamarellos-Bourboulis EJ, Pechère J-C, Routsi C et al (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46:1157–1164. https://doi.org/10.1086/529439
Giacobbe DR, Signori A, Tumbarello M et al (2018) Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-018-3441-1
Acknowledgements
We thank all the patients who participated in the database and all the members of the OUTCOMEREA Study Group (ESM 2). No financial support has been received to conduct this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical standard statement
These retrospective analyses of a prospective observational study were exempt from approval per the institutional review board or local ethics committee. In accordance with French legislation on non-interventional studies, the need for signed informed consent from the participants was waived. However, the patients and their next of kin were asked whether they were willing to participate in the database.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
134_2019_5586_MOESM4_ESM.doc
Supplemental Table E1: Demographical and clinical characteristics of patients with acute respiratory failure depending on the administration or not of a macrolide therapy within 3 days after intensive care unit admission.
134_2019_5586_MOESM5_ESM.docx
Supplemental Table E2: Multivariate logistic regression of confounding factors associated with macrolide therapy administration within 3 days following intensive care unit admission and included in the inverse probability of treatment weighting model.
134_2019_5586_MOESM6_ESM.docx
Supplemental Table E3: Unweighted and IPTW-adjusted probabilities of a better outcome in the macrolides group compared to the non-macrolide group.
Rights and permissions
About this article
Cite this article
Pons, S., Timsit, JF., Ruckly, S. et al. Impact of macrolide therapy in critically ill patients with acute respiratory failure: a desirability of outcome ranking analysis to investigate the OUTCOMEREA database. Intensive Care Med 45, 1043–1045 (2019). https://doi.org/10.1007/s00134-019-05586-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-019-05586-1